Skip to main content
SpringerLink
Log in

Medical Management of Peptic Ulcer Disease

  • Chapter
  • First Online:
The SAGES Manual of Foregut Surgery

Abstract

Peptic ulcers remain a common pathology found in the USA. With the identification of Helicobacter pylori and nonsteroidal anti-inflammatory drugs (NSAIDs) as major contributing factors in the formation of peptic ulcers, targeted medical management has become much more effective in mitigating severe complications. The widespread use of H2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and H. pylori eradicating regimens has significantly decreased the need for surgical intervention. Due in large part to these advancements, there has also been a significant decline in the number of hospitalizations for peptic ulcer disease (PUD) in the USA decreasing from 222,000 to 156,000 (29.9%) from 1993 to 2006.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg. 2010;251:51–8. https://doi.org/10.1097/SLA.0b013e3181b975b8.

    Article  Google Scholar 

  2. Espat NJ, Ong ES, Helton WS, Nyhus LM. 1990-2001 US general surgery chief resident gastric surgery operative experience: analysis of paradigm shift. J Gastrointest Surg. 2004;8:471–8. https://doi.org/10.1016/j.gassur.2004.02.002.

    Article  PubMed  Google Scholar 

  3. Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med. 2008;359:928–37. https://doi.org/10.1056/NEJMra0706113.

    Article  CAS  PubMed  Google Scholar 

  4. Schwesinger WH, Page CP, Sirinek KR, et al. Operations for peptic ulcer disease: paradigm lost. J Gastrointest Surg. 2001;5:438–43.

    Article  CAS  Google Scholar 

  5. Bardhan KD. Intermittent treatment of duodenal ulcer for long term medical management. Postgrad Med J. 1988;64(Suppl 1):40–6.

    PubMed  Google Scholar 

  6. Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949–58.

    Article  CAS  Google Scholar 

  7. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–55. https://doi.org/10.1111/j.1572-0241.2004.40014.x.

    Article  PubMed  Google Scholar 

  8. Marcus EA, Inatomi N, Nagami GT, et al. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012;36:972–9. https://doi.org/10.1111/apt.12059.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514–33. https://doi.org/10.1111/apt.13497.

    Article  CAS  PubMed  Google Scholar 

  10. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol Hepatol. 2003;17:36B–40B. https://doi.org/10.1155/2003/714124.

    Article  Google Scholar 

  11. Calvet X, García N, López T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603–9. https://doi.org/10.1046/j.1365-2036.2000.00744.x.

    Article  CAS  PubMed  Google Scholar 

  12. Flores HB, Salvana A, Ang ELR, et al. M1138 duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Gastroenterology. 2010;138:S-340. https://doi.org/10.1016/S0016-5085(10)61564-8.

    Article  Google Scholar 

  13. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol. 2002;31:128–39.

    Article  Google Scholar 

  14. Malfertheiner P, Megraud F, O’Morain CA, et al (2016) Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. gutjnl-2016-312288. https://doi.org/10.1136/gutjnl-2016-312288.

  15. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562–7. https://doi.org/10.1111/j.1572-0241.2003.t01-1-07288.x.

    Article  CAS  PubMed  Google Scholar 

  16. Salazar CO, Cardenas VM, Reddy RK, et al. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012;17:382–90. https://doi.org/10.1111/j.1523-5378.2012.00962.x.

    Article  CAS  PubMed  Google Scholar 

  17. O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of helicobacter pylori infection 2013. Helicobacter. 2013;18:58–65. https://doi.org/10.1111/hel.12075.

    Article  PubMed  Google Scholar 

  18. Liou J-M, Chen C-C, Chen M-J, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381:205–13. https://doi.org/10.1016/S0140-6736(12)61579-7.

    Article  PubMed  Google Scholar 

  19. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. https://doi.org/10.1136/bmj.f4587.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord. 2005;5:67–72.

    PubMed  Google Scholar 

  21. Coxib and traditional NSAID Trialists (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79. https://doi.org/10.1016/S0140-6736(13)60900-9.

    Article  CAS  Google Scholar 

  22. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818–28, 828.e1–5; quiz 768. https://doi.org/10.1016/j.cgh.2007.03.011.

  23. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–8.

    Article  CAS  Google Scholar 

  24. Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug–associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med. 2000;160:1455–61. https://doi.org/10.1001/archinte.160.10.1455.

    Article  CAS  PubMed  Google Scholar 

  25. Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719–26. https://doi.org/10.1056/NEJM199803123381104.

    Article  CAS  PubMed  Google Scholar 

  26. Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther. 2009;30:791–815. https://doi.org/10.1111/j.1365-2036.2009.04105.x.

  27. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ. Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9–14.

    CAS  PubMed  Google Scholar 

  28. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–13. https://doi.org/10.7326/0003-4819-152-2-201001190-00009.

    Article  PubMed  Google Scholar 

  29. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345–60. https://doi.org/10.1038/ajg.2011.480.

    Article  CAS  PubMed  Google Scholar 

  30. Behrman SW. Management of complicated peptic ulcer disease. Arch Surg Chic Ill 1960. 2005;140:201–8. https://doi.org/10.1001/archsurg.140.2.201.

    Article  Google Scholar 

  31. Tanaka R, Kosugi S, Sakamoto K, et al. Treatment for perforated gastric ulcer: a multi-institutional retrospective review. J Gastrointest Surg. 2013;17:2074–81. https://doi.org/10.1007/s11605-013-2362-7.

    Article  PubMed  Google Scholar 

  32. Crofts TJ, Park KG, Steele RJ, et al. A randomized trial of nonoperative treatment for perforated peptic ulcer. N Engl J Med. 1989;320:970–3. https://doi.org/10.1056/NEJM198904133201504.

    Article  CAS  PubMed  Google Scholar 

  33. Lau JY, Chung SC, Sung JJ, et al. Through-the-scope balloon dilation for pyloric stenosis: long-term results. Gastrointest Endosc. 1996;43:98–101.

    Article  CAS  Google Scholar 

  34. Kuwada SK, Alexander GL. Long-term outcome of endoscopic dilation of nonmalignant pyloric stenosis. Gastrointest Endosc. 1995;41:15–7.

    Article  CAS  Google Scholar 

  35. Cherian PT, Cherian S, Singh P. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy. Gastrointest Endosc. 2007;66:491–7. https://doi.org/10.1016/j.gie.2006.11.016.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Ashley H. Vernon

Authors
  1. Ashley H. Vernon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley H. Vernon .

Editor information

Editors and Affiliations

  1. University of Alabama at Birmingham , Birmingham, AL, USA

    Jayleen Grams

  2. The Ohio State University, Columbus, OH, USA

    Kyle A. Perry

  3. Brigham and Women’s Hospital, Boston, MA, USA

    Ali Tavakkoli

Rights and permissions

Reprints and permissions

Copyright information

© 2019 SAGES

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Vernon, A.H. (2019). Medical Management of Peptic Ulcer Disease. In: Grams, J., Perry, K., Tavakkoli, A. (eds) The SAGES Manual of Foregut Surgery . Springer, Cham. https://doi.org/10.1007/978-3-319-96122-4_55

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96122-4_55

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96121-7

  • Online ISBN: 978-3-319-96122-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation